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Global, regional, and national incidence, prevalence, and years lived with 
disability for 310 diseases and injuries, 1990-2015: a systematic analysis 
for the Global Burden of Disease Study 2015 
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators 
Abstract 5 
Background 
Non-fatal outcomes of disease and injury increasingly detract from the ability of the world’s population 
to live in full health, a trend largely attributable to an epidemiological transition in many countries from 
causes affecting children, to non-communicable diseases (NCDs) more common in adults. For the Global 
Burden of Diseases, Injuries, and Risk Factors Study 2015 (GBD 2015) we estimated the incidence, 10 
prevalence, and years lived with disability for diseases and injuries at the global, regional, and national 
scale, over the time period 1990 to 2015.  
Methods 
We estimated incidence and prevalence by age, sex, cause, year, and geography using a wide range of 
updated and standardised analytical procedures. Improvements included the addition of new data 15 
sources, updates to literature reviews for 85 causes, and the identification and inclusion of additional 
studies published up to November 2015 to expand the database used for estimation of non-fatal 
outcomes to 43,134 unique data sources. The most broadly used method for determining prevalence and 
incidence by cause and sequelae was DisMod-MR, a Bayesian meta-regression tool first developed for 
GBD 2010 and GBD 2013. For GBD 2015, we improved the estimation capabilities further to create 20 
DisMod-MR 2.1. For some causes, we employed alternative modeling strategies where the complexity of 
the disease was not suited to DisMod-MR 2.1 or where incidence and prevalence needed to be 
determined from other data. For GBD 2015 we created a summary indicator that combines measures of 
income per capita, educational attainment, and fertility – the Socio-demographic Index or SDI – and used 
it to compare observed patterns of health loss to the expected pattern for countries or locations with 25 
similar SDI scores. We have documented the steps involved in our analytical procedures and detailed the 
data sources used in compliance with the Guidelines for Accurate and Transparent Health Estimates 
Reporting (GATHER). 
Findings 
We generated 9.3 billion estimates from the various combinations of prevalence, incidence, and YLDs for 30 
causes, sequelae and impairments by age, sex, geography, and year. In 2015, two causes had acute 
incidences in excess of 1 billion: upper respiratory infections (17.2 billion [95% uncertainty interval 15.4-
19.2 billion]), and diarrheal diseases (2.39 billion [2.30-2.50] billion]). Eight causes of chronic disease and 
injury each affected more than 10% of the world’s population in 2015, which are permanent caries, 
tension-type headache, iron-deficiency anaemia, age-related and other hearing loss, migraine, genital 35 
herpes, refraction and accommodation disorders, and ascariasis. The impairment which affected the 
greatest number of people in 2015 was anaemia – 2.36 billion (2.35-2.37 billion) individuals were 
Confidential. Do not cite or circulate.
affected. The second- and third-leading impairments by number of individuals affected were hearing loss 
and vision loss, respectively. Between 2005 and 2015, there was little change in the leading causes of 
years lived with disability (YLDs) on a global basis. Non-communicable diseases accounted for 18 of the 40 
leading 20 causes of age-standardised YLDs on a global scale. Where rates were declining, the rate of 
decrease for YLDs was slower than that of years of life lost (YLLs) for nearly every cause included in our 
analysis. For low SDI geographies, Group I causes typically accounted for 20-30% of total disability, largely 
attributable to nutritional deficiencies, malaria, neglected tropical diseases, HIV/AIDS, and tuberculosis. 
Low back and neck pain was the leading global cause of disability in 2015 in most countries. The leading 45 
cause was sense organ disorders in 22 countries in Asia and Africa and 1 in Central Latin America; 
diabetes in four countries in Oceania; HIV/AIDS in three Southern sub-Saharan Africa countries; collective 
violence and legal intervention in two North African and Middle Eastern countries; iron-deficiency 
anaemia in Somalia and Venezuela; depression in Uganda; onchoceriasis in Liberia; and other neglected 
tropical diseases in the Democratic Republic of the Congo.  50 
Interpretation 
Ageing of the world’s population is increasing the number of people living with sequelae of diseases and 
injuries. Shifts in the epidemiological profile driven by socioeconomic change also contribute to the 
continued increase in years lived with disability (YLDs) as well as the rate of increase in YLDs. Despite 
limitations imposed by gaps in data availability and the variable quality of the data available, the 55 
standardised and comprehensive approach of the GBD study provides opportunities to examine broad 
trends, compare those trends between countries or subnational geographies, benchmark against 
locations at similar stages of development, and gauge the strength or weakness of the estimates 
available. 
Funding 60 
Bill & Melinda Gates Foundation 
Research in context 
Evidence before this study 
The Global Burden of Disease Study 2013 estimated fatal and non-fatal causes and outcomes for 306 
diseases, 2,337 sequelae, and examined the contributions of 79 risk factors to these causes of loss of 65 
health in 188 countries. Widespread policy interest and the availability of new data supported the 
expansion of subnational assessments (conducted for China, Mexico, and the United Kingdom for the first 
time in GBD 2013) for the GBD 2015 study. The GBD 2015 study contributes additional disaggregation 
into new areas of subnational estimation, the inclusion of new causes, and innovations in the use of 
metrics and measurements.  70 
Added value of this study 
The GBD 2015 study incorporates an expanded set of geographies and subnational estimations that 
include Brazil, China, India, Japan, Kenya, Mexico, Saudi Arabia, South Africa, Sweden, the United 
Kingdom, and the United States. This study is in compliance with the Guidelines for Accurate and 
Transparent Health Estimates Reporting (GATHER) recommendations. The addition of estimation of non-75 
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fatal outcomes for Ebola, motor neuron disease, and subtypes of carcinoma and leukemia; the 
improvement in computational efficiency and model transparency; and new applications of a Socio-
demographic Index. 
Implications 
This study provides the most comprehensive assessment to date of the patterns and levels of acute and 80 
chronic diseases and injuries and years lived with disability across the globe. Our comparisons of the 
patterns of observed disability and health loss against the expected levels relative to position on a Socio-
demographic Index, provide needed insight for policy directions based on nationally specific health 
challenges. The GBD 2015 study entails a complete reanalysis of levels and trends from 1990 to 2015; the 
time series published here supersedes the results of the GBD 2013 study. The expansion of geographic 85 
units, from 296 in GBD 2013 to 519 for GBD 2015, is envisaged to continue so as to sustain comparability 
over time and across all geographies.  
Introduction  
Although significant progress has been made toward reducing mortality and extending life expectancy 
throughout the world over the last few decades, the epidemiological transition is manifest in the growing 90 
importance of non-fatal diseases, outcomes, and injuries which pose – partly as a consequence of 
declining death rates – a rising challenge to the ability of the world’s population to live in full health. 
Complementing information on deaths by age, sex, cause, geography, and time with equally detailed 
information on disease incidence, prevalence, and severity, is key to a balanced debate in health policy. 
For this reason, the Global Burden of Disease Study (GBD) uses the disability-adjusted life year (DALY) 95 
combining years of life lost (YLLs) due to mortality and years lived with disability (YLDs) in a single metric. 
One DALY can be thought of as one lost year of ‘healthy life’. The sum of DALYs in a population can be 
thought of as the gap between the population’s current health status and an ideal situation where the 
entire population lives to an advanced age, free of disease. Assessments of how different diseases lead to 
multi-morbidity and reductions in functional health status are important for both health system planning1 100 
and a broader range of social policy issues such as the appropriate age for retirement in some 
countries.2,3 Many challenges in making standardized estimates of non-fatal health outcomes are similar 
to those affecting mortality estimates (including variations in case definitions, data collection methods, 
variable quality of data collection, conflicting data, and missing data) but are compounded by sparser and 
more varied data sources, the need to characterise each disease by its disabling sequelae, or 105 
consequence(s), and to quantify the severity of these consequences. The standardized approach of the 
annual GBD updates addresses these measurement problems to enhance comparability between causes, 
by geography, and over time.  
The estimates from GBD 2013 drew attention to large increases in the number of years lived with 
disability (YLDs) over the previous decade, while rates of YLDs for most causes remained stable or showed 110 
only small declines.4 The GBD 2013 assessment largely attributed increases in the number of YLDs to 
musculoskeletal disorders, mental and substance use disorders, neurological disorders, and chronic 
respiratory diseases, as well as population growth and ageing. GBD 2013 also brought attention to 
increased divergence in trends between mortality and morbidity for many causes. YLDs as a proportion of 
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DALYs increased globally – a manifestation of the continuing epidemiological transition in low- and 115 
middle-income countries. Declines in mortality from diseases such as pneumonia, diarrhea, maternal and 
neonatal disorders, and a lack of progress in reducing YLD rates, continued to drive a transition toward a 
greater global volume of YLDs.  
Along with broad recognition that data from some regions were sparse, and that more and higher-quality 
data in general would likely improve estimation, there have been useful debates on the GBD results in the 120 
literature. These have focused on the analysis or presentation of individual diseases, such as changes over 
time in GBD estimates of dementia,5 the accuracy of HIV incidence estimates,6,7 the absence of sepsis as a 
disease,8,9 the quality of some cancer registry data,10 and the absence of mental disorders as sequelae of 
neglected tropical diseases.11 The GBD empirical approach to measuring the public’s view of health state 
severity has generated substantial interest with questions about the relative importance of different 125 
dimensions of health,12,13 the quantification of health loss per se,14,15 and discussions of the transferability 
of judgements about relative health to conventional notions of disability and dependence.5 In each cycle 
of the GBD, we seek to improve the estimates, reflecting published and unpublished critique through the 
acquisition of new data, expansion of the network of collaborators, changes in how data are corrected for 
bias, advances in modeling techniques, and the targeted expansion of the GBD cause list. 130 
The primary objective of this component of the GBD was to use all available data of sufficient quality to 
generate reliable and valid assessments of disease and injury sequelae incidence, prevalence, and YLDs 
for all 310 causes in the GBD cause hierarchy for 591 locations in the GBD spanning the period 1990 to 
2015. We describe change over time and between populations in relation to where countries fall on the 
development continuum.16 Continuing efforts to improve data and code transparency are an important 135 
part of the GBD cycle. These results thus supersede any previous publications about the GBD on disease 
incidence, prevalence, and YLDs. 
Methods 
The overall logic of our analytical approach is illustrated for the entire non-fatal estimation process in 
Figure 1. The appendix to this paper provides a single source for detail of inputs, analytical processes, and 140 
outputs and methods specific to each cause. This study complies with the Guidelines for Accurate and 
Transparent Health Estimates Reporting (GATHER) recommendations (Appendix Table 1).17 
The geographies included in GBD 2015 have been arranged into a set of hierarchical categories composed 
of seven super-regions and a further nested set of 21 regions containing 195 countries and territories. 
Eight additional subnational assessments were undertaken for Brazil, China, India, Japan, Kenya, Saudi 145 
Arabia, South Africa, Sweden, and the United States (see Appendix Table 2). For this paper we present 
data at the national and territory level. 
The GBD cause and sequelae list is organized hierarchically (see Appendix Table 3). At Level 1 there are 
three cause groups: communicable, maternal, neonatal, and nutritional diseases (Group 1 diseases); non-
communicable diseases; and injuries. These Level 1 aggregates are subdivided at Level 2 of the hierarchy 150 
into 21 cause groupings. The disaggregation into Levels 3 and 4 contains the finest level of detail for 
causes captured in GBD 2015. Sequelae of diseases and injuries are organized at Levels 5 and 6 of the 
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hierarchy. The finest detail for all sequelae estimated in GBD is at Level 6 and is aggregated into summary 
sequelae categories (Level 5) for causes with large numbers of sequelae. Sequelae in GBD are mutually 
exclusive and collectively exhaustive, and thus our YLD estimates at each level of the hierarchy sum to the 155 
total of the level above. Prevalence aggregations are estimated at the level of individuals who may have 
more than one sequela or disease, and therefore are not additive. 
The cause and sequelae list expanded following feedback from GBD 2013 and input from GBD 2015 
collaborators. Eight causes for which non-fatal outcomes are estimated were added: Ebola, motor-neuron 
disease, environmental heat and cold exposure, four subtypes of leukemia, and two subtypes of non-160 
melanoma skin cancer (Appendix Table 3). The incorporation of these changes expanded the cause list 
from the 301 causes with non-fatal estimates examined in GBD 2013, to 310 causes with non-fatal 
estimates and from 2,337 to 2,619 unique sequelae at Level 6 of the hierarchy. At the newly created Level 
5 of the hierarchy there are 154 summary sequela categories. Appendix Table 4 provides a list of 
International Classification of Diseases version 9 (ICD-9) and version 10 (ICD-10) codes for all GBD causes 165 
and the nature of injury categories. 
A complete set of age-, sex-, cause-, and geography-specific incidence and prevalence numbers and rates 
were computed for the years 1990, 1995, 2000, 2005, 2010, and 2015. In this paper we focus on trends 
for main and national results over the last decade, from 2005 to 2015, together with more detailed 
results for 2015. Online data visualizations at http://vizhub.healthdata.org/gbd-compare provide access 170 
to results for all GBD metrics. 
Non-fatal modeling strategies vary significantly between causes. Figure 1 outlines the general process of 
non-fatal outcome estimation from data inputs to finalization of YLD burden results; step 3b of that 
process identifies alternative modeling approaches employed for certain causes. These approaches are 
illustrated in greater detail in Appendix Figure 1b. The starting point for non-fatal estimation is the 175 
compilation of data sources identified through systematic analysis and extractions based on pre-
determined inclusion and exclusion criteria (see Appendix Section 2.1). As part of the inclusion criteria, 
we defined disease- or injury-specific reference case definitions and study methods, as well as alternative 
allowable case definitions and study methods which were adjusted for if we detected a systematic bias. 
We used 15 types of primary data sources representing disease prevalence, incidence, mortality risk, 180 
duration, remission, or severity in the estimation process (oval shapes in Figure 1).  
For this iteration of the study, we updated data searches through systematic data and literature reviews 
for 85 causes through October 2015. For other causes, input from GBD collaborators resulted in the 
identification and inclusion of a limited number of additional studies published after January 2013. Data 
were systematically screened from household surveys archived in the Global Health Data Exchange 185 
(ghdx.healthdata.org), sources suggested to us by in-country experts, and surveys identified in major 
multinational survey data catalogs and Ministry of Health and Central Statistical Office websites. Case 
notifications reported to the WHO were updated through 2015. Citations for all data sources used for 
non-fatal estimation in GBD 2015 are provided in searchable form through a new web-tool 
(http://ghdx.healthdata.org/). A description of the search terms employed for cause-specific systematic 190 
reviews, inclusion and exclusion criteria, and the preferred and alternative case definitions and study 
methods are detailed by cause in Appendix Section 3. 
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Hospital inpatient data were extracted from 284 country-year and 976 subnational-year combinations 
from 27 countries in North America, Latin America, Europe, and New Zealand. Outpatient encounter data 
were available from the US, Norway, Sweden, and Canada for 48 country-years. For GBD 2015, we also 195 
accessed aggregate data derived from claims information in a database of US private and public insurance 
schemes, for the years 2000, 2010, and 2012. From the linked claims data we generated several 
correction factors to account for bias in health service encounter data from elsewhere, which were 
largely available to us aggregated by ICD code and by primary diagnosis only. First, for chronic conditions, 
we estimated the ratio between prevalence from primary diagnoses and prevalence from all diagnoses 200 
associated with a claim. Second, we used the claims data to generate the average number of outpatient 
visits per condition. Similarly, we generated per person discharge rates from hospital inpatient data in the 
US and New Zealand, the only sources with unique patient identifiers available for GBD 2015.  
As in GBD 2013, we calculated a geographic and temporal data representativeness index (DRI) of non-
fatal data sources for each cause or impairment. The DRI represents the fraction of countries for which 205 
any incidence, prevalence, remission, or mortality risk data were available for a cause. This metric 
quantifies data availability, not data quality. The overall DRI and period-specific DRI measures for each 
cause and impairment are presented in Appendix Tables 5a and 5b. DRI ranged from 90% for nine causes, 
including tuberculosis and measles, to less than 5% for acute hepatitis C and the category of other 
exposures to mechanical forces. Required case reporting resulted in high DRI values for notifiable 210 
infectious diseases; the network of population-based registries for cancers resulted in a DRI above 50%. 
DRI values ranged from 6.1% in North Korea to 91.3% in the United States. Many high-income 
countries, as well as Brazil, India, and China, had DRI levels above 63%; data availability was low in 
several countries, including Equatorial Guinea, Djibouti, and South Sudan.  
In addition to the corrections applied to claims and hospital data, a number of other adjustments were 215 
applied including age-sex splitting, bias correction, adjustments for underreporting of notification data, 
and computing expected values of excess mortality. In GBD 2013, we estimated expected values of excess 
mortality from prevalence or incidence and cause-specific mortality rate (CSMR) data for a few causes 
only, including tuberculosis and COPD. In order to achieve greater consistency between our cause of 
death and non-fatal data we adopted this strategy systematically for GBD 2015. We matched every 220 
prevalence data point (or incidence data for short-duration conditions) with the CSMR value 
corresponding to the age range, sex, year, and location of the data point. The ratio of CSMR to prevalence 
is conceptually equivalent to an excess mortality rate.  
To estimate non-fatal health outcomes in previous iterations of GBD, most diseases and impairments 
were modelled in DisMod-MR, a Bayesian meta-regression tool originally developed for GBD 2010 (step 225 
3a in Figure 1).18 DisMod-MR was designed to address statistical challenges in estimating non-fatal health 
outcomes, and for synthesizing often sparse and heterogeneous epidemiological data. For GBD 2015, the 
computational engine of DisMod-MR 2.1 remained unchanged but we substantially rewrote the code that 
organizes the flow of data and settings at each level of the analytical cascade. The sequence of estimation 
occurs at five levels: global, super-region, region, country, and where applicable, for subnational locations 230 
(Appendix Figure 2). At each level of the cascade the DisMod-MR 2.1 computational engine enforces 
consistency between all disease parameters. For GBD 2015, we generated fits for the years 1990, 1995, 
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2000, 2005, 2010, and 2015. We log-linearly interpolated estimates for the intervening years in each 5-
year period. The source code for DisMod-MR 2.1 engine, as well as the code that organizes the flow of 
input data, settings, and outputs are available at http://ihmeuw.org/dismod-ode with further detail in the 235 
Appendix Section 2.3. 
As in previous iterations of GBD, custom models were created for a short list of causes for which the 
compartment model underpinning DisMod (susceptible, diseased, and dead) was insufficient to capture 
the complexity of the disease or for which incidence and prevalence needed to be derived from other 
data. Step 3b of Figure 1 describes the development of custom models with greater detail shown in 240 
Appendix Figure 1b and Appendix Section 3 for HIV/AIDS, TB, malaria, cancer, neonatal disorders, 
infectious diseases for which we derived incidence from seroprevalence data, and infectious diseases for 
which we derived incidence from cause of death rates and pooled estimates of the case fatality 
proportion.  
As in GBD 2013, we estimated the country-age-sex-year prevalence of nine impairments – step 4 of 245 
Figure 1. Impairments in GBD are conditions or specific domains of functional health loss which are 
spread across many GBD causes as sequelae and for which there are better data to estimate the 
occurrence of the overall impairment than for each sequela based on the underlying cause. Overall 
impairment prevalence was estimated using DisMod-MR 2.1 except for anaemia, for which spatial-
temporal Gaussian process regression (ST- GPR) methods were applied. We constrained cause-specific 250 
estimates of impairments, as in the 19 causes of blindness, to sum to the total prevalence estimated for 
that impairment. Anaemia, epilepsy, hearing loss, heart failure, and intellectual disability were estimated 
at different levels of severity. 
In step 5, sequelae were further deﬁned in terms of severity for 194 causes at Level 4 of the hierarchy (Figure 
1a). We generally followed the same approach for estimating the distribution of severity as in GBD 2013. 255 
For Ebola, we created a health state for the infectious disease episode with duration derived from average 
hospital admission times, and a health state for ongoing post-infection malaise and joint problems based on 
four follow-up studies19–22 from which we derived an average duration. The health states for the subtypes of 
leukemia and non-melanoma skin cancer were the same as the general cancer health states. For motor-
neuron disease we accessed the Pooled Resource Open-Access ALS Clinical Trials (PROACT) database 260 
containing detailed information on symptoms and impairments for over 8,500 patients who took part in 
trials.23  
We used the same disability weights as in GBD 2013. A complete listing of the lay descriptions and values 
for the 235 health states used in GBD 2015 is provided in Appendix Table 6. 
In step 7, we estimated the co-occurrence of different diseases by simulating 40,000 individuals in each 265 
geography–age–sex–year combination as exposed to the independent probability of having any of the 
sequelae included in GBD 2015 based on disease prevalence. We tested the contribution of dependent 
and independent comorbidity in the US Medical Expenditure Panel Surveys (MEPS) data, and found that 
independent comorbidity was the dominant factor even though there are well-known examples of 
dependent comorbidity. Age was the main predictor of comorbidity such that age-specific 270 
microsimulations accommodated most of the required comorbidity correction. Taking dependent 
comorbidity into account changed the overall YLDs estimated in the MEPS data by only 2.5% (and ranging 
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from 0.6% to 3.4% depending on age) in comparison to assuming independent comorbidity.24 Additional 
details of the comorbidity simulation process are provided in the Appendix Section 2.7. 
We report 95% uncertainty intervals for each quantity in this analysis using 1,000 samples from the 275 
posterior distribution of prevalence and 1,000 samples of the disability weight to generate 1,000 samples 
of the YLD distribution. The 95% uncertainty interval is reported as the 25th and 975th values of the 
distribution. We report on significant changes in disease estimates between countries or over time if the 
change was observed in more than 950 of the 1,000 samples computed for each result. For GBD 2015, we 
computed age-standardised prevalence YLD rates from the updated world population age standard 280 
developed for GBD 2013.25 Less common diseases and their sequelae were included in 35 residual 
categories (Appendix Table 7). For 22 of these residual categories, estimates were made from 
epidemiological data on incidence or prevalence. For 13 residual categories, we estimated YLDs by 
multiplying the residual YLL estimates by the ratio of YLDs to YLL from the estimates for explicitly 
modelled Level 3 causes in the same disease category.  285 
In GBD 2013, SDS was computed based on a principal components analysis of income per capita, 
educational attainment, average age of the population and the total fertility rate.26 For GBD 2015, we 
excluded mean age of the population because it is directly affected by death rates. To improve 
interpretability for GBD 2015, we computed a Socio-demographic Index (SDI) similar to the computation 
of the Human Development Index.27 In the SDI, each component was weighted equally and rescaled from 290 
zero (for the lowest value observed in the time period 1980 to 2015) to one (for the highest value 
observed) for income per capita and average years of schooling and the reverse for the total fertility rate. 
The final SDI was computed as the geometric mean of each of the components. SDI ranged from 0.060 in 
Mozambique in 1987 to 0.978 in District of Columbia, United States in 2015.  
Role of the funding source 295 
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full access to all the data in the study and had final 
responsibility for the decision to submit for publication. 
Results  
We generated over 9.3 billion outcomes of incidence, prevalence, and YLDs for 310 diseases, injuries, and 300 
aggregate categories; 2,619 unique and aggregate sequelae; nine impairments; 63 age-sex groups; 591 
geographies; and 25 years from 1990 to 2015. Each of these 9.3 billion estimates was calculated 1,000 
times to determine uncertainty intervals. Here, we present key summary findings on global incidence of 
short duration diseases, global prevalence of long-term conditions, global prevalence of impairments, 
global numbers and rates of YLDs and changes from 2005 to 2015, global YLL and YLD rates of change, 305 
patterns of comorbidity, the expected changes in the composition of YLDs with SDI, and country findings 
of leading causes of YLDs.  
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Global incidence and prevalence  
Conditions of less than three months’ duration and injuries with incidence of more than 1 million cases 
per year in 2015 are listed in Table 1. There were two conditions with incidence greater than 1 billion: 310 
upper respiratory infections (17.2 billion [95% uncertainty interval 15.4 - 19.2 billion]), and diarrheal 
diseases (2.39 billion [2.30- 2.50 billion]). A further 13 diseases and injuries caused between 100 million 
and 1 billion incident cases a year and 16 diseases and injuries had incident cases between 10 million and 
100 million per year (Table 1).  
The disease and injury sequelae with a duration of greater than three months and a global prevalence 315 
greater than 1% in 2015 are presented in Table 2, aggregated to the cause level. Prevalence for 
impairments is presented at the bottom of Table 3. Eight out of 56 high-prevalence causes affected more 
than 10% of the world’s population in 2015. A further 48 causes affected between 1% and 10% of the 
world’s population (Table 2). Although many of these causes are not among the dominant causes of YLDs 
due to comparatively low average disability weights, some, such as headaches, gynecological conditions, 320 
oral conditions, and skin diseases, put great demands on health system resources by their sheer numbers. 
Anaemia was the most common of our nine impairment conditions, affecting 2.36 billion (2.35-2.37 
billion) persons in 2015. The next most common impairments were hearing impairment of greater than 
20 dB (1.33 billion [1.26-1.40 billion]), vision loss (940 million [905-974 million]), developmental 
intellectual disability (153 million [114-191 million]), infertility (113 million [93.4-136 million]), heart 325 
failure (40.0 million [38.6-41.4 million]), and epilepsy (39.2 million [34.3-43.7 million]) (Table 3).  
Supplementary Results 1, Tables 2-9 show the prevalence estimates of the underlying causes of these 
impairments. Iron deficiency was the cause of anaemia in more than half of all cases. Over 90% of hearing 
loss was classified as age-related or other hearing loss. The largest number of people with vision loss had 
uncorrected refraction error. Idiopathic developmental intellectual disability, idiopathic female infertility, 330 
and idiopathic epilepsy were the most common causes of their impairments. Ischaemic heart disease was 
the most common cause of heart failure.  
Global causes of disability  
Global trends in YLDs 2005 to 2015 
GBD 2015 included the assessment of 2,619 sequelae at Level 6 of the GBD cause hierarchy, including 335 
1,316 sequelae from injuries, that contributed to the global burden of disability. Causes at Level 4 of the 
hierarchy that resulted in 30 million or more YLDs in 2015 included low back pain, major depressive 
disorder, age-related and other hearing loss, and neck pain. Figure 2 compares the leading causes of 
global YLDs in 2005 and 2015, using the cause breakdowns at Level 3 of the GBD cause hierarchy. Among 
the 10 leading causes of YLDS, iron-deficiency anaemia and depressive disorders switched places in ranks 340 
in positions three and four, diabetes rose from the eighth to sixth position, migraine dropped from 
position six to seven, and other musculoskeletal dropped from rank seven to eight (Figure 2).   
Estimates of prevalence and YLDs at the global level for 2005 and 2015 for each cause are presented in 
Table 3 (full detail at the sequela level is available in Supplementary Results 1, Table 1). Prevalence and 
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age-standardized YLDs for 21 Group 1 diseases decreased significantly and by greater than 10%, including 345 
measles, African trypanosomiasis, diphtheria, lymphatic filariasis, and rabies.  
Age-standardized YLD rates for all maternal causes and sequelae combined decreased between 2005 and 
2015, whereas overall age-standardized YLDs for neonatal disorders increased 3.11% (-0.32-6.79%) from 
2005 to 144 YLDs per 100,000 (109-185 YLDs per 100,000) in 2015, and age-standardized YLD rates 
decreased and absolute numbers of cases increased for nutritional deficiencies. Age-standardized YLD 350 
rates attributable to hepatitis A, B, C increased and E decreased. The number of individuals with chronic 
hepatitis C infection increased from 121 million (108-133 million) in 2005 to 142 million (127-157 million) 
in 2015.  
In 2005, non-communicable diseases (NCDs) accounted for 23 of the leading 25 causes of age-
standardized YLDs worldwide and 23 of the 25 leading causes in 2015 (Figure 2). Although diabetes rose 355 
only 2 ranks in the list of leading cause of YLDs, from position 8 to 6 between 2005 and 2015, the increase 
in age-standardized rate was 5.4% (3.2%-7.5%). Musculoskeletal conditions occupied three of the leading 
25 causes of disability in both 2005 and 2015; low back and neck pain remained the single largest cause 
with little change in rates. However, age-standardized rates of YLDs increased for osteoarthritis 3.90% 
(3.00-4.83%) by 2015. Depressive disorders were the fourth-leading cause of disability in 2005 and the 360 
third-leading cause of disability in 2015, and age-standardized YLD rates associated with the condition 
increased marginally (1.0% [0.5-1.5%]). Age-standardized rates of YLDs from alcohol use disorders 
decreased after 2005, (4.5% [2.3-6.4 %]), whereas disability due to drug use disorders increased by 8.2% 
(6.2-10.2%). 
In contrast to global trends for NCDs, both relative ranks and age-standardized YLD rates declined for 365 
most injuries. Falls, which were the 13th-leading cause of disability in 2005, fell to the 15th rank, and age-
standardized YLD rates decreased (8.58% [5.23-12.2 %]). Other unintentional injuries decreased in global 
rank from 27th in 2005 to 34th in 2015, and age-standardized YLD rates decreased by 16.7% (15.7-17.9%). 
The leading causes of disability varied considerably with age (Figure 3). The leading cause in children 
under 5 was iron-deficiency anaemia followed by skin diseases, protein-energy malnutrition, and 370 
diarrhea. In older children, iron-deficiency anaemia, skin diseases, asthma and mental disorders such as 
conduct, autistic spectrum, and anxiety disorders were top-10 causes. In adolescents and young adults, 
iron-deficiency anaemia, skin diseases, depression, low back and neck pain, and migraine led the rankings. 
Other mental disorders such as anxiety disorders and schizophrenia appeared in the top 10 in this age 
range. In middle-aged adults, musculoskeletal disorders dominated the top rankings followed by mental 375 
disorders, especially depression. Diabetes and sense organ disorders were more prominent causes of 
disability in middle age. In the elderly, sense organ disorders were the top-ranked cause of disability. 
Musculoskeletal disorders remained a dominant source of disability, and COPD entered the top 10. In the 
oldest age groups ischaemic heart disease and Alzheimer and other dementia made their first appearance 
in the top 10. 380 
Changes in age-standardized YLDs and YLLs over time 
We examined the trends in YLDs and YLLs in a scatterplot (Figure 4). YLLs decreased for the majority of 
causes. For Group I causes and injuries the decline in YLLs was accompanied by a decline in YLDs albeit at 
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a slower pace. The exceptions were neonatal encephalopathy, hemolytic disease and other neonatal 
jaundice, leishmaniasis, meningitis, hepatitis, and sexually transmitted diseases with increasing YLD rates 385 
between 1990 and 2015. A few Group I conditions and injuries had a faster decline in YLDs than YLLs: 
intestinal infections, obstructed labour, and neonatal sepsis. The only non-communicable diseases with a 
faster decline in YLDs compared to YLLs were epilepsy and cervical cancer. Another small number of non-
communicable diseases saw an increase in YLDs and YLLs, including drug use disorders, diabetes and 
Parkinson disease. Non-communicable diseases with declining YLLs but increasing YLDs included cancers 390 
of prostate,  testes, uterus, kidney, colorectum and pancreas, melanoma,  and congenital disorders. A few 
of the cancers (stomach, and Hodgkin), rheumatic heart disease,  asthma, COPD, acute 
glomerulonephritis, peptic ulcer disease, gastritis, hernia, and gall bladder disease saw YLLs and YLDs 
declining but with faster decline in YLLs compared to YLDs. The rate of change in YLDs for the main drivers 
of non-fatal health loss, musculoskeletal disorders and mental disorders, was small.  395 
Global distribution of disability weight across individuals 
Figures 5a and b show the global distribution of individuals from our comorbidity microsimulation by six 
categories of disability, age, and sex for the highest and lowest SDI quintile. The six categories of disability 
are no disability, very mild disability (disability weight less than or equal to 0.01), mild disability (from 0.01 
to 0.05 inclusive), moderate (from 0.05 to 0.1 inclusive), severe (from 0.1 to 0.3 inclusive), and profound 400 
(greater than 0.3). In 2015, most of the world’s population experienced mild or greater disability. Having 
no disability at all was most common in children. After age 25, the proportion of the population having no 
disability became progressively smaller and by age 55 in low SDI countries and age 75 in high SDI 
countries nearly everyone had some form of disability. Very mild to moderate disability (i.e., those with a 
disability weight of 0.1 or less) was common in childhood and young adults but was replaced by more 405 
severe disability with increasing age. The patterns were similar for both sexes apart from a much larger 
amount of disability in women at ages over 80 in the top SDI quintiles reflecting the much higher average 
age of women in this age category. For policy considerations around the age at retirement in ageing 
populations, it is noteworthy that from age 60 onwards more than half of the population experienced 
severe or worse disability. The extent to which this loss of health limits or precludes the ability to work 410 
depends on the nature of the impairments and the type of employment in elderly workers with that level 
of disability. 
Expected changes in disease profile with higher SDI 
Figures 6a and 6b depict changes in patterns of disability by level of SDI for age-standardized and all age 
YLD rates per 100,000. Age-standardized YLD rates gradually decreased with increasing SDI in both sexes 415 
(Figure 6a). The cause composition of YLDs somewhat varied across levels of SDI; these differences were 
largely derived from absolute levels of disability due to communicable causes and nutritional deficiencies, 
and to a lesser extent, maternal and neonatal disorders. Age-standardized YLD rates due to NCDs and 
injuries were relatively similar at all SDI levels. 
Across levels of SDI, mental and substance disorders, musculoskeletal disorders, and other non-420 
communicable diseases were consistently among leading causes of age-standardized YLD rates. Anaemia 
led to generally higher rates of age-standardized of YLDs among women than men across levels of SDI, 
but the largest imbalance occurred at SDI levels between 0.10 and 0.50. Disability from injuries exacted a 
larger burden for men than women, particularly at lower levels of SDI. 
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Without adjustments for population age structure (Figure 6b), the impact of ageing populations and 425 
causes of disability that disproportionately affect older individuals become prominent. At all levels of SDI, 
total YLDs per 100,000 did not notably differ by sex; instead, the cause composition of disability showed 
greater differences. Below an SDI of 0.25, communicable causes accounted for 30-45% of total disability, 
primarily due to nutritional deficiencies, malaria, and NTDs. YLDs per 100,000 due to musculoskeletal 
disorders, particularly low back and neck pain and other musculoskeletal disorders, increased 430 
substantially from low to high SDI, with a more pronounced increase beginning at an SDI of 0.6. This rise 
was particularly evident among women. 
Trends in age-standardized YLDs per capita 
Globally, age-standardized YLDs per capita – an indicator of overall disability experienced per person in a 
given place – moderately decreased for both sexes between 1990 and 2015 (see Supplementary Results 435 
1, Figure 1). Age-standardized YLDs per capita were consistently higher for women than men at the global 
level. For both sexes, YLDs per capita were generally higher for lower levels of SDI. YLDs per capita were 
noticeably larger for low-SDI and low-middle-SDI groups than for other SDI levels (i.e., high SDI, high-
middle SDI, and middle SDI), which were more similar to each other.  
Leading causes of YLDs and deviations from expected levels based on SDI 440 
Clear, though varied, patterns emerged across and within GBD regions in comparing observed levels of 
YLDs due to leading causes of disability to levels expected on the basis of SDI. Figure 7 displays ratios of 
observed and expected YLDs for the leading 10 causes at level three of the GBD hierarchy in 2015, color-
coded by the magnitude of differences between observed and expected YLDs. 
Globally, low back and neck pain was the leading cause of disability in 2015. Two mental disorders, major 445 
depressive and anxiety disorders, were the third and ninth leading causes of global disability, and 
diabetes was the sixth-leading driver of disability. Iron-deficiency anaemia was the only Group 1 cause 
among the leading 10 causes for global YLDs (ranked fourth). Sensory disorders and skin diseases ranked 
second and fifth, respectively. Low back and neck pain was the leading global cause of disability in 2015 in 
most countries. The leading cause was iron-deficiency anaemia in 27 countries; HIV/AIDS in all six 450 
Southern sub-Saharan African countries; depression in five Eastern sub-Saharan Africa countries; other 
NTDs in Angola, Democratic Republic of the Congo, and Gabon; sense organ disorders in Comoros and 
Myanmar; diabetes in Fiji and Marshall Islands; war in Lebanon and Syria; and onchocerciasis in Liberia. 
Regional, country, territory, and selected subnational results 
Low back and neck pain was the leading cause of disability in all high income countries in 2015. However, 455 
ratios of observed to expected YLDs from low back and neck pain ranged from 0.60 for Singapore to over 
1.59 in Norway. Most high-income countries experienced higher than expected levels of disability due to 
depressive disorders. The US and Australia were the only two high-income countries where drug use 
disorders were a top 10 cause of disability and observed levels of YLDs were much higher than expected. 
South Korea’s ratio of observed-to-expected levels of YLDs due to diabetes exceeded 1.30, while Japan’s 460 
diabetes-related disability was lower than expected on the basis of SDI. In the UK, observed disability due 
to asthma was well above expected levels. 
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In 2015, low back and neck pain was the leading cause of YLDs for all but two countries in Latin America 
and the Caribbean; Haiti, Venezuela were the exceptions, with iron-deficiency anaemia as the leading 
causes of disability for both countries. Disability due to diabetes surpassed expected levels by at least a 465 
factor of two for 6 countries and territories: Antigua, Barbados, Dominica, Puerto Rico, Trinidad Tobago, 
and the Virgin Islands. Peru, however, experienced a ratio of less than 0.6 for observed and expected 
YLDs for diabetes.  
In 2015, low back and neck pain was the leading cause of YLDs for 24 out of 28 countries and territories of 
Southeast Asia, East Asia, and Oceania. Other leading cause of disability were sensory disorders in 470 
Myanmar; diabetes in Fiji and the Marshall Islands, and iron-deficiency anaemia in Papua New Guinea. 
Although low back and neck pain was their primary cause of disability, many countries experienced levels 
far lower than expected given their SDI, including Thailand (0.73), Indonesia (0.76), and Malaysia (0.75). 
Observed YLDs due to depressive disorders were often lower than expected, with 22 countries recording 
ratios below 0.80. Conversely, numerous geographies recorded YLD ratios exceeding 2.00 for diabetes 475 
(e.g., Taiwan [2.29]).  
Beyond low back and neck pain, which was the leading cause of YLDs for 3 of 5 countries in South Asia in 
2015 (with India and Pakistan being the exception), a mixture of causes accounted for the region’s main 
causes of disability; this heterogeneity likely reflects the diversity of countries in the region and their 
places along the development spectrum. Iron-deficiency anaemia was the first-leading cause and low 480 
back and neck pain was the second-leading cause of YLDs in both India and Pakistan, whereas sensory 
disorders, other musculoskeletal disorders, and Iron-deficiency anaemia ranked second for disability in 
Nepal, Bangladesh, and Bhutan respectively. YLDs due to anxiety were lower than expected in all 
countries in the region except Bangladesh. 
In the GBD super-region of Central Europe, East Europe, and Central Asia, low back and neck pain was the 485 
leading cause of disability in every geography in 2015; while all countries in Eastern and Central Europe 
recorded higher than expected YLD ratios for most of their top 10 causes, Central Asia mostly had lower 
than expected or as expected YLD ratios. Sensory disorders and depressive disorders, were the second- 
and third-leading causes of disability in this super-region, respectively.  
Sizeable discrepancies occurred for observed and expected YLDs based on SDI throughout North Africa 490 
and the Middle East, likely reflecting the uneven achievements in development found in this region. Low 
back and neck pain was the primary driver of YLDs in the region. Exceptions to this were, Lebanon and 
Syria, for which war caused most disability in 2015, and Afghanistan for which iron-deficiency was the 
leading cause. Depression, sensory disorders, diabetes, and ranked second, third and fourth, respectively, 
for the region. Observed YLDs due to diabetes consistently exceeded expected levels, with two countries 495 
posting ratios higher than 3.00 (ie, Qatar [3.12], and the UAE [3.52]). Iran and Morocco recorded much 
higher disability due to drug use disorders than expected based on SDI. 
In comparison with the rest of the world, relative ranks of cause-specific disability – and their ratios of 
observed to expected values – were vastly different in sub-Saharan Africa. Of the 46 countries within the 
super regions, nine had low back and neck pain as the leading cause of YLDs in 2015. In Southern sub-500 
Saharan Africa, HIV/AIDS was the leading cause of disability for all countries. Iron-deficiency anaemia 
ranked as the leading cause of YLDs for 11 countries in Western sub-Saharan Africa. For the remaining 
Confidential. Do not cite or circulate.
countries, low back and neck pain was primarily the leading cause of YLDs; Liberia, the exception, had 
onchocerciasis as its leading cause of disability. Malaria and various NTDs caused more YLDs than 
expected in most West African countries. For Eastern sub-Saharan Africa, sense organ, iron deficiency, 505 
depressive disorders and low back and neck pain were leading causes of YLDs in 2015. In Central sub-
Saharan Africa, skin diseases were consistently among the leading three to four causes of disability in this 
region. HIV/AIDS resulted in far more YLDs than expected based on SDI, with the Equatorial Guinea, and 
Central African Republic recording ratios of observed versus expected YLDs higher than 2.00.  
Discussion 510 
We used 43,134 data sources to estimate the incidence and prevalence of 2,619 sequelae of 310 causes 
for 591 geographies for the years 1990, 1995, 2000, 2005, 2010, and 2015. After accounting for variation 
over time and across geographies in case definitions, disease assays, survey instruments, and coding 
practice, and using standardized modeling approaches to deal with missing data, conflicting data, and a 
range of sampling and non-sampling errors, we characterized the global and national patterns in non-fatal 515 
health outcomes. We found that global age-standardized YLDs per capita decreased slightly in the last 25 
years from 0.114 (0.085-0.147) in 1990 to 0.110 (0.082-0.141) per capita in 2015, a total decrease of 
3.69% (3.12-4.25%) over a generation (see Supplementary Results 1, Figure 1). The ageing of the world’s 
population and the general increase in YLDs per capita with age resulted in an increase in global YLDs per 
capita. Within this overall pattern, 133 out of 310 causes had statistically significant decreases in YLDs per 520 
capita between 2005 and 2015, compared to 82 causes with statistically significant increases in YLDs per 
capita over the same time period. The most important contributors to global YLDs were musculoskeletal 
disorders (18.5% [16.4-20.9%] of all YLDs in 2015), mental and substance use disorders (18.4% [15.6-
21.2%]), and the category of other non-communicable disorders (17.9% [15.0-21.7%]), dominated by 
hearing loss, vision impairment, and skin disorders.  525 
Typology of diseases based on YLDs and YLLs 
The comparison of trends in age-standardized YLDs and YLLs provides insight into the drivers of 
differences in rates of increases and decreases for diseases and injuries. Diseases and injuries can be 
parsed into four groups. The first of these are a small set of conditions including causes such as drug use 
disorders and skin cancer for which age-standardized rates of both YLDs and YLLs increased at a rate 530 
greater than 0.4% per year from 2005 to 2015. A second category of diseases includes those where YLDs 
are increasing but YLLs are declining, including conditions such as thyroid cancer, cirrhosis, and neonatal 
encephalopathy. One explanation for this pattern is that risk factors broadly defined are causing an 
increase in incidence, while access to effective treatment has improved enough to continue reducing 
mortality. For another category of conditions, YLDs are essentially constant but YLLs are declining. This 535 
grouping is quite large and includes many of the major causes of disability such as musculoskeletal 
disorders, various neurological disorders, and a number of cancers. For many infectious causes, declines 
are occurring for both YLLs and YLDs but are much faster for YLLs; this pattern is to be expected if access 
to effective treatment is decreasing deaths but not reducing prevalence or incidence. The last category 
includes conditions where declines are equal, if not slightly higher, for YLDs including ischemic heart 540 
disease, falls, cervical cancer, and other injuries. Examination of differential trends by region or country 
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may provide insights into the role of access to treatment in reducing YLLs and, conversely, the role of 
increasing or decreasing risks and social determinants in driving changes in disease incidence and 
prevalence. More detailed exploration of these differential trends is warranted in future work.  
Disability and retirement age 545 
As life expectancy has steadily increased in most countries there have been calls in some high-SDI 
countries to extend retirement ages to reflect these changes in survival.28–30 A critical factor in these 
debates is whether individuals are living longer and have higher average levels of functional health at 
each age or not. In this study, we found that age-standardized YLDs per capita declined, but rather slowly, 
over the period 2005 to 2015. Comparison of trends in age-standardized YLDs and YLLs by cause show 550 
that the main causes of YLDs are not declining and in some settings may be increasing. Other than a 
somewhat slower rate of improvement for YLDs at oldest age (80+), age discontinuities are not 
observable in these patterns. Ultimately, the debate on retirement age will hinge on the skill sets required 
for different types of work, whether work contributes to diminished or improved functional health status, 
and societal expectations for retirement. Our findings suggest that the burden from mental and 555 
behavioral disorders and musculoskeletal disorders, frequent causes of early retirement31,32 in terms of 
age-specific prevalence has not declined much over time; the continued prevalence of these and other 
conditions associated with increasing age may limit the capacities of an older work force.   
Epidemiological transition 
The analysis of YLD rates by Level 2 causes as a function of SDI shows a very different picture than 560 
reported for YLLs. At the lower end of the SDI spectrum, incremental increases in SDI are associated with 
reductions in both age-standardized YLDs and all-age YLD rates spurred by decreases in disability from 
neglected tropical diseases and anaemia as well as declines in tuberculosis, diarrhea, pneumonia, 
meningitis, and other infectious diseases. At levels of SDI above 0.8 (see Appendix Table 8 for SDI values 
for each country), age-standardized rates of health loss increase slightly, attributable to higher rates of 565 
mental disorders and substance use disorders, musculoskeletal conditions, and neurological conditions. In 
this phase of the epidemiological transition, this increase in rates, although small, combined with 
population ageing, results in increases in YLDs per 100,000. The rising average YLD per capita rates have 
health system implications; a larger fraction of the population is likely to need care for many conditions. 
Some of these conditions are currently costly to manage.33 The increase in health care costs per individual 570 
in the population that occurs once an SDI of 0.8 is exceeded is a predictable component of the 
epidemiological transition; these costs should be anticipated during the health planning processes of 
countries in that stage of the transition.  
Disease-specific issues 
Musculoskeletal disorders 575 
Musculoskeletal conditions continue to be a leading cause of disability globally and more so when taking 
into account that additional musculoskeletal burden from long-term sequelae of fractures and 
dislocations is classified under injuries in GBD. A key component of healthy ageing is maintaining mobility 
and a key public health intervention recommended for improving health outcomes for all chronic diseases 
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is physical activity. Painful musculoskeletal conditions increase with age and are a significant threat to 580 
mobility, compromising health more broadly.34–36 Even if cures for musculoskeletal disorders are not yet 
available, the clinical goal of preventing disability is attainable.37,38  
Mental and substance use disorders 
Consistent with the findings of earlier GBD studies, GBD 2015 confirms the large contribution of mental 
and substance use disorders to global disability. For the first time, in GBD 2015 we found a positive 585 
relationship between conflict and depression and anxiety, albeit with wide uncertainty. This is due to 
sparse and low-quality data on these disorders in post-conflict countries. Going forward we plan to make 
separate estimates for post-traumatic stress disorder in GBD, which may add considerably more data 
from conflict settings and show a stronger relationship. GBD results have provided an evidence base to 
support global action such as a stated commitment by the World Bank and WHO to make mental health a 590 
global development priority39 and the consideration of mental and substance use disorders in shaping the 
Sustainable Development Goals.40 There are cost-effective interventions able to reduce the burden 
imposed by mental and substance use disorders, including in low- and middle-income countries.41 
Recent increases in deaths attributable to drug use in the United States have resulted in considerable 
policy and media attention. In our assessment, the 10 countries with the highest prevalence of opioid 595 
dependence in 2015 were Iran, United Arab Emirates, Russia, Morocco, United States, Australia, Ukraine, 
Tunisia, Belarus, Canada, and Iraq. Among these countries, we estimated the highest excess mortality 
from opioid dependence in the Eastern European countries at about twice the level of that in the US, 
Canada, and the North African and Middle Eastern countries; the lowest rate among these highly 
prevalent countries was in Australia. Within the US, prescription opioids have been estimated to account 600 
for 37% of drug overdose deaths in 2013.42,43 The availability of overdose response treatments in the 
form of naloxone kits to laypersons has also accelerated.44 An alternative approach is opioid substitution 
therapy to reduce overdose risk. The intensity at which countries employ harm-reduction strategies such 
as needle exchange and opioid substitution programs follows an inverse pattern,45 with the most intense 
programs in Australia but very rare use of such strategies in Eastern Europe, suggesting that embracing 605 
harm reduction is an effective means of reducing drug deaths.   
Diabetes mellitus 
To obtain standard estimates for health loss due to diabetes for GBD 2015 using both fasting plasma 
glucose (FPG) means and standard deviations as well as diabetes prevalence, we re-extracted all available 
data from 1990 through 2015. Across studies, we found 20 different case definitions for diabetes. We 610 
also included, wherever possible, studies reporting on mean FPG but not diabetes prevalence, using a 
regression between mean FPG and diabetes prevalence from studies reporting on both. We have also 
made the assessment of diabetes prevalence more consistent with cause of death data on diabetes. Our 
improved efforts at measuring the prevalence of diabetes confirms the increase in global age-
standardized incidence, prevalence, and YLDs. Of note, the increase in YLDs at the global scale is greater 615 
than the increase in YLLs which reflects improved access to treatments that lower case fatality. The rise of 
diabetes, related to the global increase in body mass index,46 given the costs of treating the disease47 and 
the related increases in cardiovascular risks, poses one of the more important challenges to health 
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systems in coming years. This is particularly the case in regions with high prevalence such as Central 
America, North Africa and the Middle East, and Oceania.   620 
Ezzati et al48 and the International Diabetes Federation (IDF)49 have estimated diabetes prevalence for 
many countries; the intra-class correlation coefficient for the estimates from Ezzati et al and the GBD for 
2015 is 0.74, and for the IDF estimates 0.65. These relatively large differences appear to stem from the 
inclusion of cause of death data in the modeling for GBD and also due to the inclusion of self-reported 
diabetes prevalence in the study by Ezzati et al.48 In GBD, these sources were excluded from our analyses 625 
because of changing patterns in the prevalence of known and unknown diabetes in surveys that varies 
with geography, making it difficult to crosswalk these studies. 
Dementia 
Brayne and colleagues50,51 reported that age-specific prevalence of Alzheimer’s was declining in the UK. 
Of four studies with comparable measurements over time in the US that were reviewed, one showed a 630 
decline, while no change in prevalence was observed in the remaining studies.52,53 Our assessment of age-
standardized prevalence showed that Alzheimer’s and other dementias declined slowly in the United 
Kingdom, 3.69% (2.53 - 4.85%) from 2005 to 2015, but remained relatively constant in the rest of the 
world. The decline may be due to reductions in vascular dementias rather than reductions in Alzheimer’s 
and other dementias. Our assessment also suggests that the number of individuals with Alzheimer’s 635 
disease increased from 21.7 million (18.9-24.8 million) globally in 1990 to 46.0 million (40.2-52.7 million) 
in 2015. While it is useful to know that age-standardized rates may be starting to decline, if slightly, the 
rapid increase in absolute number of cases points to the major challenge that dementia presents to 
societies with increasing life expectancy. This is comparable to the most recent estimates from the World 
Alzheimer Report 2015 that estimated 46.8 million people living with dementia in 2015. However, there is 640 
less agreement about new cases per year: The World Alzheimer Report estimates 9.9 million new cases of 
dementia per year in 2015 compared to 6.44 million (5.52-7.45 million) new cases in 2015 in GBD. The 
World Alzheimer Report separately analysed prevalence and incidence whereas we use DisMod-MR 2.1 
to produce internally consistent prevalence and incidence estimates. We observed a fundamental 
disagreement in the underlying incidence and prevalence data in many countries and decided to exclude 645 
incidence data from our modelling approach, putting greater trust in prevalence studies than incidence 
studies arguing that the point of incidence in dementia is more difficult to establish than prevalence when 
the diagnosis over time becomes more established. 
Hepatitis C 
The availability of new medical treatments for chronic hepatitis C has driven considerable interest in the 650 
data on prevalence for this disease. Available treatments are highly effective but costly.54 Some programs 
have been launched in Egypt and other lower-SDI countries that offer treatment at lower cost. Good data 
on the number of courses of treatment that have been delivered are not widely available. Given the 
numbers with chronic infection and the potential for cure, tracking the fraction treated each year should 
be undertaken. Even in high-income countries such as the US, the fraction of those treated among who 655 
would benefit from treatment is not yet available.   
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Malaria 
Our assessment of malaria prevalence and incidence in high burden sub-Saharan Africa was based on the 
Malaria Atlas Project spatial analysis of prevalence surveys conducted across Africa between 2000 and 
2015.55,56 The dynamic map of malaria prevalence was updated for GBD 2015 and extended back to 1980. 660 
Children under the age of 5 in sub-Saharan Africa showed a remarkable 33.5% (24.8-46.0%) decline in 
incidence from the 2005 peak of 0.78 (0.56-0.96) cases per person per year to 0.52 (0.33-0.71) in 2015. 
Yet there were 81.7 million (52.0-111.7 million) incident cases in this age group in 2015. The decline in 
children was more rapid than observed for older age groups. In adolescents and adults incidence dropped 
by 30.0% (17.2-39.2%) and 21.1% (15.3-26.9%), respectively, and resulted in 58.7 million (37.7-91.5 665 
million) and 53.3 million (40.7-67.5 million) incident cases, respectively, in 2015. The observed decreases 
in malaria incidence underscore the remarkable impact of the scale-up of antimalarial interventions57 
across Africa in the last decade.55 Sustaining the levels of these interventions is critical to continue to 
reduce malaria morbidity on the continent, avoid resurgence, and improve on these levels vital to global 
aspirations for malaria eradication.58 Overall, we estimate 286.9 million (219.7-377.3 million) cases of 670 
malaria worldwide in 2015, while the World Malaria Report (WMR) 2015 reports 214 million (149-303 
million) cases in 2015.59 Of these cases, the WMR estimates that 88% of cases occurred in the WHO 
African Region (188 million) while we estimate 66.1% – or 189.4 million (151.7-239.4 million) cases for 
GBD. Outside of Africa, the WMR reports 26 million cases versus our estimate of 97.3 million (50.2-181.8 
million), but both sets of estimates feature identical regional rankings among the six WHO regions with 675 
malaria. Increasing convergence in estimates is expected as dynamic maps of malaria prevalence and 
incidence become available for all malaria-endemic countries outside of Africa. 
Tuberculosis 
We added new data from tuberculosis (TB) prevalence surveys conducted in Indonesia, Ghana, and 
several subnational locations in India. Our analysis of TB relied on prevalence surveys, case notifications 680 
and cause-specific mortality estimates. We used the expert judgment values about the case-detection 
rates (CDRs) from the WHO as an initial guide by how much notifications need to be increased to reflect 
incidence of all TB, but relied on DisMod-MR 2.1 to find an estimate that is consistent with available 
prevalence and cause-specific mortality rates. We found that, particularly in older age groups, our 
estimated CDR often falls below the all-age CDR of WHO. In GBD 2013, we used a relative risk approach to 685 
predict the proportion of HIV-infected individuals with TB. In GBD 2015, we improved our modelling 
strategy by making use of more abundantly available data on the proportions of HIV-TB cases among all 
TB cases from the WHO case notifications to separate out HIV-TB from all forms of TB. In our modelling of 
TB, we have not separately estimated the incidence and prevalence related to multi-drug-resistant TB 
(MDR-TB). Given the great policy interest in MDR-TB, we plan to include estimates for MDR-TB in future 690 
rounds of the GBD. Our global TB (all-forms) incidence estimate (10.2 million [9.2-11.5 million] cases in 
2015) is slightly higher than that of the WHO (9.6 million cases in 2014), but we estimate a slightly larger 
fraction of HIV-TB (13.0%) than the WHO (12.0%). Our list of countries with high burden of TB is 
consistent with that of WHO with a few exceptions. Afghanistan and Cambodia are lower in our 
estimates, and surpassed by Ukraine and Angola.  695 
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Cardiovascular diseases 
Ageing and population growth have led to a growing number of people living with atherosclerotic 
vascular disease globally, despite the decline in incident myocardial infarction and ischemic stroke in high-
income regions. Rising levels of obesity and diabetes in many countries makes this an area of major 
concern for global health. Increased attention will need to be directed toward this highly treatable set of 700 
conditions. Health systems will need to improve the delivery of cost-effective therapies such as blood 
pressure and cholesterol-lowering medications while efforts continue to focus on decreasing tobacco 
smoking, improving diet, and increasing physical activity. Investments in universal primary care and public 
health campaigns need to be balanced against the need to improve access to emergency care, including 
the strengthening of pre-hospital systems and expanded access to revascularization therapies.  705 
Cancer 
The International Agency for Research on Cancer (IARC) last produced cancer estimates by country, age, 
sex, and cancer site for 2012 for the GLOBOCAN project60 The total estimated cancer incidence from 
GLOBOCAN for 2012 was 14.1 million individuals. By comparison, GBD 2015 estimated 18.6 million (18.0-
19.4 million) new cases of cancer in 2015, which includes cases of non-melanoma skin cancer. GLOBOCAN 710 
used nine different methods to estimate incidence, which precludes the calculation of uncertainty for 
those estimates. The GBD relies on the strength of the mortality estimates and transformation of the 
mortality estimates to incidence, taking into account uncertainty associated with both the mortality 
estimates and with the mortality to incidence ratios. Until high-quality cancer incidence is available in all 
countries, the GBD approach – which maximizes the amount of data used to determine incidence 715 
estimates – is highly beneficial.  
Vision loss  
Globally, 34.3 million (30.7-38.0 million) people are blind, an additional 24.3 million (21.6-27.6 million) 
have severe vision impairment, 214 million (193-237 million) have moderate vision impairment, and 663 
million (638-690 million) have near vision impairment in 2015. Combined, vision loss accounts for 24.5 720 
million (17.0-34.5 million) YLDs, and is the third-largest impairment after anaemia (77.9 million [52.4-
111.4 million] YLDs) and hearing loss (46.2 million [31.6-63.2 million] YLDs). YLDs from vision loss are 
slightly lower than those for anxiety disorders, which rank ninth globally. Largely due to ageing, 
substantial increases occurred from 2005 to 2015 in the number of people suffering from blindness 
(increasing by 23.3% [21.9-24.6%]), severe visual impairment (24.3% [22.4-26.0%]), moderate visual 725 
impairment (22.0% [20.1-23.7%]), and near vision impairment (22.5% [20.9-24.0%]). Most causes of 
vision loss can be prevented or cured using cost-effective interventions.61,62  
Chronic kidney disease 
In comparison with our GBD 2013 estimates we are estimating global prevalence of CKD to be lower by a 
third. Data on chronic kidney disease at younger ages are sparse. We increased the number of data points 730 
below the age of 30 from 20 to 51, and that led to considerably lower prevalence estimates at these ages. 
We have used different strategies for estimating deaths versus YLDs secondary to chronic kidney disease 
due to other causes. In our cause of death analysis, deaths secondary to many of the causes typically 
categorized within “CKD other,” such as cystic disease and other congenital renal diseases, were already 
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counted under the primary disease following the principles of the ICD and thus could not be re-counted 735 
within the “CKD other” category. In comparison, for the YLD analysis we count chronic kidney disease 
from these causes in the “CKD other” category. This difference in the classification of morbidity and 
mortality from “CKD other” is driven by the underlying nature of the data on causes of death and 
prevalence. In future GBD versions, we plan to make explicit estimates of death and YLDs for polycystic 
kidney disease, an important component of the other category. 740 
Emerging diseases 
Emerging and re-emerging infectious diseases pose a persistent yet dynamic challenge to global health63 
and to the GBD study. GBD 2015 has included Ebola in response to the devastating outbreak in West 
Africa starting in 2013,64 whereas we have not captured the recent expansions of Chikungunya65 and Zika 
virus across the Americas,66 for instance. Quantifying the impact of newly emerging epidemic diseases is 745 
difficult because the formal reporting of the disease events may significantly lag the first presentation of 
cases. As a result, contemporary events such as the significant deviation from baseline levels in reported 
congenital abnormalities in Brazil in 2015,67 now established to be associated with Zika virus,68 will need 
to be incorporated in GBD 2016.  
Advances in data and analysis 750 
DisMod-MR 
For GBD 2015, we improved the estimation for subnational units in DisMod-MR 2.1 compared to GBD 
2013 and made substantive efforts to standardize the modelling approach across diseases. Three changes 
had an important impact on our estimates. First, the cascade was implemented such that national 
estimates informed the priors for subnational estimation (in GBD 2013, each subnational unit was treated 755 
as a country within a GBD region). Second, wherever possible we improved the linkage in the estimation 
between cause-specific mortality and disease incidence and prevalence by the systematic inclusion of 
estimated excess mortality data to provide more informative priors for each location in the geographical 
hierarchy. Third, in GBD 2010, and to a lesser degree in GBD 2013, many DisMod-MR models did not 
include fixed effects of country covariates for incidence or prevalence. Spatial heterogeneity was largely 760 
estimated from the random effects. For GBD 2015, we systematically tested the inclusion of more fixed 
effects in DisMod-MR 2.1 models including, where appropriate, variables related to the risk factor 
exposures we estimate for each disease.  
Disability weights 
For GBD 2015, we have not incorporated any new population-based data on disability weights; we have 765 
used the same disability weights as for GBD 2013. The current set of disability weights were based on 
population surveys in nine countries and an open internet survey. To date, these studies have not found 
systematic variation in disability weights across populations or within populations as a function of 
education, income per capita, or other variables. In the future, we hope that more population surveys on 
disability weights will continue to be conducted to enrich the database for disability weight estimation. 770 
Given that we have not been able to collect disability weights in every location included in the GBD, it is 
possible that disability weights may vary systematically across communities. Even if this were to be 
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confirmed empirically, for global standardized comparisons we would still use the global average disability 
weights; country analyses, however, might use local disability weights. Until there is evidence of 
systematic variation across communities, however, this remains a theoretical and not a practical 775 
consideration. Given the close correlation between the internet survey and the population-based surveys, 
we are considering the implementation of an open rolling internet survey to collect more data on 
disability weights including new or revised health state descriptions.   
GATHER compliance 
Providing all documentation for data sources, establishing access to the datasets used in modelling, and 780 
posting the code has been a labor-intensive activity; GBD 2015 is compliant with the new GATHER 
guidelines as a result.17 Posting code, we believe, will stimulate other researchers to explore the methods 
used in GBD estimation of non-fatal outcomes and hopefully lead to suggestions for improved estimation. 
With a steadily growing set of co-investigators and a widening community interested in global health 
estimation, the enhanced transparency of GBD will improve the efficacy of the overall effort.  785 
Using claims data 
For the US we used claims data for selected conditions. These data were particularly useful in the 
estimation of state-by-state prevalence for some conditions. Claims data, however, have important 
potential biases. Because of exclusion of some disadvantaged groups from insurance, disease rates may 
be different in those that are covered than from the general population.69,70 As the claims dataset 790 
included information from Medicaid and Medicare, the coverage schemes for low-income citizens and 
the elderly in the US, the bias toward underestimation may not be so great. Indeed, we found that for 
many diseases, such as asthma, diabetes, or rheumatoid arthritis, the claims data were consistent with 
high-quality survey estimates. A potential problem of overestimation exists, because visits to rule out a 
diagnosis can be coded to the diagnosis. Others working with claims have counted diagnoses only if they 795 
had appeared at least twice during a year. Applying such a restriction would have led to rejecting 44% to 
68% of skin conditions, such as acne, psoriasis, or scabies, where one would expect that even at a single 
visit a diagnosis can be reliably made. As we tend to adjust the claims data used in DisMod-MR 2.1 if a 
systematic bias is detected from population-based sources, such as NHANES or other quality surveys, we 
believe our estimates have not been influenced much by this problem. The potential for claims data in 800 
the GBD analysis is large; in countries with universal health access, claims data may overcome the 
problems of non-responder bias in survey data, which tend to lead to underestimates of the true 
population prevalence or incidence.  
Self-reported functional health status  
We found only modest progress in high-SDI countries in reducing age-standardized YLDs per capita over 805 
the last 25 years. There are, however, reports in the literature of substantial improvements based on self-
rated health.71,72 In the US, these improvements appear to be survey program-specific and have not been 
reported in all data systems.71 Nevertheless, more work is needed to understand the divergent trends 
between our assessment of YLDs per capita and self-rated health. Item response theory has been used in 
some fields to identify changing response patterns for single items compared to the pool of all items.73 810 
Item response theory cannot capture systematic changes that affect a set of items, and anchoring 
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vignettes have been proposed as a strategy to deal with these challenges.72,74 In the era of increased 
interest in measuring functional health status, more exploration of the reasons for the divergence from a 
sequelae-based approach to measuring functional health status used in GBD versus an overall self-rating 
will be an important avenue of future research.  815 
Crosswalks 
Because of the diversity of data sources available we estimated the statistical relationship between 
measurements taken using different case definitions, different assays, different survey items, or different 
ascertainment methods to a reference category. We used these statistical relationships to crosswalk each 
type of data to the reference category. Crosswalks are a critical dimension in the GBD analysis; in most 820 
cases we estimate these crosswalks from within DisMod-MR 2.1. If crosswalks were believed to vary 
substantially by age, sex, or location, these crosswalks were estimated outside of DisMod-MR 2.1 and 
adjusted data were used as inputs. Where data are sparse, the estimated crosswalks can shift 
substantially when new studies are identified that inform the crosswalk. With each iteration of the GBD, 
we have recognized the critical nature of the crosswalk analysis for data processing. We believe that more 825 
research is needed in future iterations of GBD to standardize the approaches used for estimating 
crosswalks across conditions and risk factors, and for propagating uncertainty in crosswalks into the final 
results.  
Data gaps 
We have described the availability of data by cause and geography over different time periods, 830 
highlighting very large gaps in information availability. The data availability by country ranged from 6.1% 
in North Korea to 91.3% in the United States (see Appendix Figure 3 and Tables 5a-b). Among the top-
five causes of YLDs, data availability was rather poor. Low back pain, iron-deficiency anaemia, major 
depressive disorder, other hearing loss, and neck pain all have data representativeness indices below 
50%. Because of the broad overview provided of major data sources for disease incidence and 835 
prevalence, GBD provides a framework to assist countries in prioritizing the collection of new data to 
inform better monitoring of functional health status. By setting clear reference case definitions and data 
collection methods (as stated Appendix Section 3), GBD can also provide guidance on how to collect 
information most relevant to population health measurement. 
Future directions for GBD  840 
With each cycle of the GBD we expect, given current interest in subnational assessments, to report 
increasingly granular results. These subnational findings will be of important national policy interest, but 
the discipline of examining the evidence for each community and modelling at the more granular level 
will, we believe, improve the quality of the national estimation as well. Additions to the cause list will 
continue to be driven by policy interest, such as the need to incorporate Zika, to split diabetes into 845 
separate estimates for type 1 and type 2 and by adding diseases to our cause list that are main 
contributors to large residual categories such as other cardiovascular disease, other musculoskeletal 
disorders, and other neurological disorders. We plan to continue to expand our network of topic-specific 
and country collaborators to enhance the quality of our estimates through their feedback and by 
enhancing the amount of data we can bring to bear on GBD estimation. Our experience with the 850 
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countries we currently work with more closely to make subnational estimates is that this effort greatly 
enhances access to valuable data sources, particularly administrative datasets on inpatient and outpatient 
episodes and unpublished surveys.  
Limitations 
The GBD 2015 study has some key limitations. First, although we have sought to capture and include in 855 
our estimation many sources of uncertainty, we have not captured all sources. We have not been able to 
routinely capture uncertainty due to different model specifications in our results. We do not have the 
ability to reflect the uncertainty due to data sources that exist but of which we are not aware. 
Subnational collaborations in China and Mexico revealed many data sources not captured in previous 
iterations of the GBD study. Inclusion of these data sources can lead to shifts in estimates that are outside 860 
the previously estimated 95% uncertainty intervals.  
Second, within DisMod-MR 2.1 we estimate the average relationship between different types of studies 
for reporting on a specific outcome such as the difference between 12-month recall and point prevalence 
in a survey. These estimated relationships from within the DisMod-MR 2.1 likelihood estimation are used 
to adjust the data to a reference case definition or study design. These estimated adjustment factors are 865 
themselves uncertain, which increases the overall uncertainty in our estimation. More standardization in 
data collection would be highly desirable and would reduce our dependence on the relatively challenging 
estimation process involved in crosswalks.  
Third, for some conditions the data available to estimate excess mortality by age and sex and to capture 
how excess mortality changes with development status is very limited. There are likely many unpublished 870 
sources of information in some countries that could be usefully brought to bear on the challenge of 
estimating the age-sex-year-location levels of excess mortality.  
Fourth, the micro-simulation step of this study assumes that prevalence within an age-sex-location-year 
group of different sequelae is independent. Although this is clearly known not to be the case for some 
pairs of conditions, the independence assumption provides reasonable overall adjustments for 875 
comorbidity. Progress in incorporating dependent comorbidity has been difficult because information on 
the correlation structure of prevalence is extremely limited and only available for a minor fraction of all 
possible pairs of conditions in the GBD study.  
Fifth, we estimated separate DisMod-MR 2.1 models for 1990, 1995, 2000, 2005, 2010, and 2015. 
Independent estimation of each time period implies that the uncertainty intervals for each period are also 880 
independent. Further, compositional bias in the data available in different time periods may lead to 
spurious time trends. A more appealing strategy would be to simultaneously estimate the trends in 
incidence, excess mortality, and remission by age and sex consistent with all the available data for a 
geography on prevalence, incidence, remission, excess mortality, and cause-specific mortality by age and 
sex. DisMod-MR 2.1 does not allow for time-varying trends in incidence, excess mortality, and remission, 885 
but a prototype DisMod-MR AT (age and time) has been developed and is being tested. Allowing for all 
rates to change at different paces over age and time increases the number of parameters that need to be 
estimated by orders of magnitude.  
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Sixth, we have emphasized in the reporting of results the changes from calendar year 2005 to calendar 
year 2015, although we have estimated results for 1990, 1995, 2000, 2005, 2010 and 2015 and 890 
interpolated for the years in between. For some conditions, reporting the change from 2005 to 2015 
(such as for Ebola) does not capture the major epidemic in West Africa in 2014. Likewise, disasters and 
wars are often concentrated in a single year; comparisons of any two years can provide misleading 
inferences about trends.  
Seventh, for a few conditions, tetanus, neonatal sepsis, rabies, and diphtheria, we estimate disease 895 
incidence from estimates of mortality and the inverse of the case-fatality rate estimated from available 
studies. When the case-fatality rate is very low, these estimates of incidence are highly sensitive to very 
small changes in the estimated case-fatality rate and have large uncertainty intervals.  
Eighth, while extraordinary efforts have gone into vetting the results by GBD researchers and the 
collaborator network, there are likely some findings that have not been carefully scrutinized. Making all 900 
results and underlying data available, and having an increasing number of visualization tools, are 
successful strategies we will keep expanding to meet our goal of producing the highest-quality global 
health data to our growing audience of policymakers, researchers, the media, and the general population.  
Conclusion 
The GBD study seeks to quantify the prevalence and incidence of the major sequelae for a comprehensive 905 
list of diseases and injuries; given the diversity of data sources, the range of biases in these sources, and 
the gaps in availability, this is a challenging task. Despite the limitations, the standardized and 
comprehensive approach of the GBD study provides useful insights. We believe users of the findings, 
including the wealth of country- and cause-specific detail available in the supplementary results, can 
usefully examine the broad trends for their country or subnational geography, benchmark against 910 
geographies at a similar level of development, and understand the strength or weakness of these 
estimates. Regular quantification of health is particularly important as the new health-related targets of 
the Sustainable Development Goals have broadened the health agenda throughout the world. At the 
same time, development and transformations in the risks to health experienced by different groups in the 
world are leading to some broad transformations in health. Everyone needs to have access to the 915 
timeliest, valid, reliable, and local information possible to enrich debates on how to accelerate health 
progress in all communities.    
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Tables and Figures 
Table 1. Global incidence of short-duration sequelae (duration less than 3 months) for Level 4 causes with 
incidence greater than 1 million cases per year 920 
Table 2. Global prevalence of longer-duration sequelae (duration greater than 3 months) for Level 4 
causes with prevalence greater than 1% 
Table 3. Prevalent cases and YLDs for 2015, percent change, and percent change of age-standardized 
rates between 2005 and 2015 for all Level 4 causes and nine impairments 
Figure 1: Analytical flowchart for the estimation of cause-specific YLDs by location, age, sex, and year for 925 
GBD 2015 
Figure 2. Leading 30 level 3 causes of global years lived with disability (YLDs) for both sexes combined, 
1990, 2005 and 2015, with percentage change in number of YLDs, and all-age and age-standardized rates 
Figure 3. Leading ten level 3 causes of age-specific years lived with disability (YLDs) in 2015, with rates of 
change from 2005 to 2015 930 
Figure 4. Global annualized rate of change in age-standardized years of life lost (YLLs) and years lived with 
disability (YLDs) for level 3 causes between 1990 and 2015 
Figure 5a&b. Population pyramids with the number of individuals, by age and sex, grouped by severity of 
their disability weight (DW) for all comorbid conditions combined into no disability, very mild disability 
(DW 0 to 0.01), mild disability (DW 0.01 to 0.05), moderate disability (DW 0.05 to 0.1), severe disability 935 
(DW 0.1 to 0.3), and very severe disability (DW greater than 0.3) for geographies for the top and bottom 
quintiles of Socio-demographic Index in 2015 
Figure 6a. The expected relationship between age−standardized years lived with disability (YLD) rates per 
100,000 people for the 21 GBD Level 2 causes and the Socio−demographic Index 
Figure 6b. The expected relationship between all-age years lived with disability (YLD) rates per 100,000 940 
people for the 21 GBD Level 2 causes and the Socio−demographic Index 
Figure 7. Leading ten causes of years lived with disability (YLDs) with the ratio of observed YLDs to YLDs 
expected on the basis of Socio-Demographic Index in 2015, by location  
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